116406-19-0Relevant articles and documents
The First Total Synthesis of Racemic Chebulic Acid
Christoffers, Jens,Kieslich, David
, (2022/01/22)
The first total synthesis of racemic chebulic acid is reported, which is the aglycon of several antioxidant ingredients of the fruit of the Terminalia chebula tree. The route started with the straightforward preparation of an indanone-based β-oxoester fro
Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury
Chen, Lingfeng,Jin, Yiyi,Chen, Hongjin,Sun, Chuchu,Fu, Weitao,Zheng, Lulu,Lu, Min,Chen, Pengqin,Chen, Gaozhi,Zhang, Yali,Liu, Zhiguo,Wang, Yi,Song, Zengqiang,Liang, Guang
, p. 361 - 375 (2017/12/07)
Myeloid differentiation protein 2 (MD2) is an essential molecule which recognizes lipopolysaccharide (LPS), leading to initiation of inflammation through the activation of Toll-like receptor 4 (TLR4) signaling. Caffeic acid phenethyl ester (CAPE) from propolis of honeybee hives could interfere interactions between LPS and the TLR4/MD2 complex, and thereby has promising anti-inflammatory properties. In this study, we designed and synthesized 48 CAPE derivatives and evaluated their anti-inflammatory activities in mouse primary peritoneal macrophages (MPMs) activated by LPS. The most active compound, 10s, was found to bind with MD2 with high affinity, which prevented formation of the LPS/MD2/TLR4 complex. The binding mode of 10s revealed that the major interactions with MD2 were established via two key hydrogen bonds and hydrophobic interactions. Furthermore, 10s showed remarkable protective effects against LPS-caused ALI (acute lung injury) in vivo. Taken together, this work provides new lead structures and candidates as MD2 inhibitors for the development of anti-inflammatory drugs.
TUBULIN BINDING AGENTS
-
Paragraph 0193; 0194; 0195; 0196; 0197; 0198; 0199, (2015/02/18)
The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.
Synthesis of diverse analogues of Oenostacin and their antibacterial activities
Srivastava, Vandana,Darokar, Mahendra P.,Fatima, Atiya,Kumar,Chowdhury, Chinmay,Saxena, Hari Om,Dwivedi, Gaurav R.,Shrivastava, Kunal,Gupta, Vivek,Chattopadhyay,Luqman, Suaib,Gupta,Negi, Arvind S.,Khanuja, Suman P.S.
, p. 518 - 525 (2008/03/12)
Several diverse analogues of Oenostacin, a naturally occurring potent antibacterial phenolic acid derivative, have been synthesized. A small library with more than forty analogues having different aromatic rings and varied side chains has been achieved through solution phase synthesis. Some of these analogues, that is, 22, 23 and 42, possessed potent antibacterial activities against Staphylococcus epidermidis and Staphylococcus aureus having EC50 ranging from 0.49 to 0.67 μM as compared to Oenostacin (EC50 = 0.12 μM).
Unsymmetrical cyclic diamine compound
-
, (2008/06/13)
A cyclic diamine compound of formula (1): wherein A is (CH2)n, (CH2)n—CH═CH, CO—(CH2)n or CO—(CH2)n—CH═CH, in which n is a number of 0 to 3; Z represents a formula (2) or (3): in which R1, R2, R4, R5 and R6 are individually a hydrogen atom, alkyl group, alkoxy group, halogen atom or nitro group; R3 is a hydrogen atom, alkyl group, alkoxy group, halogen atom, nitro group, naphthyl group, or phenyl group which may be substituted by 1 to 3 substituents selected from the group consisting of alkyl groups, alkoxy groups, halogen atoms, a nitro group and a phenyl group; and X and Y are individually CH or a nitrogen atom; and m is 1 or 2; an acid-addition salt thereof, or a hydrate thereof, and a medicine containing such a compound.
ANTIHYPERTENSIVE QUINAZOLINE DERIVATIVES
-
, (2008/06/13)
Novel quinazoline compounds and antihypertensive compositions containing said compounds are disclosed; said compounds having the formula: STR1 wherein R 1 is a hydrogen atom or an alkyl group having 1-5 carbon atoms;R 2 is a group of the formula STR2 in which Y is a hydrogen atom, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-5 carbon atoms, an alkenyloxy group, a methylenedioxy group, a nitro group, a halogen atom, a trifluoromethyl group, an acyloxy group, a hydroxy group, an unsubstituted or substituted amino group or a condensed benzene nucleus and m is an integer of 1-3 inclusive, or a group of the formula STR3 in which X is an oxygen atom, a sulfur atom or a carbon-nitrogen double bond and Z is a hydrogen atom, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-5 carbon atoms, a nitro group or a halogen atom; and n is an integer of 2-3 inclusive;provided that, when R 2 is the said group STR4 n is 2 and R 1 is a hydrogen atom or, when R 2 is the said group STR5 n is 2 or 3 and R 1 is a hydrogen atom or the said alkyl group and a pharmaceutically acceptable acid addition salt thereof.
